Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 28;6(4):e57.
doi: 10.2196/resprot.6902.

Engaging Patients and Caregivers Managing Rare Diseases to Improve the Methods of Clinical Guideline Development: A Research Protocol

Affiliations

Engaging Patients and Caregivers Managing Rare Diseases to Improve the Methods of Clinical Guideline Development: A Research Protocol

Dmitry Khodyakov et al. JMIR Res Protoc. .

Abstract

Background: Clinical guidelines provide systematically developed recommendations for deciding on appropriate health care options for specific conditions and clinical circumstances. Up until recently, patients and caregivers have rarely been included in the process of developing care guidelines.

Objective: This project will develop and test a new online method for including patients and their caregivers in this process using Duchenne muscular dystrophy (DMD) care guidelines as an example. The new method will mirror and complement the RAND/UCLA Appropriateness Method (RAM)-the gold standard approach for conducting clinical expert panels that uses a modified Delphi format. RAM is often used in clinical guideline development to determine care appropriateness and necessity in situations where existing clinical evidence is uncertain, weak, or unavailable.

Methods: To develop the new method for engaging patients and their caregivers in guideline development, we will first conduct interviews with experts on RAM, guideline development, patient engagement, and patient-centeredness and engage with Duchenne patients and caregivers to identify how RAM should be modified for the purposes of patient engagement and what rating criteria should patients and caregivers use to provide their input during the process of guideline development. Once the new method is piloted, we will test it by conducting two concurrently run patient/caregiver panels that will rate patient-centeredness of a subset of DMD care management recommendations already deemed clinically appropriate and necessary. The ExpertLens™ system-a previously evaluated online modified Delphi system that combines two rounds of rating with a round of feedback and moderated online discussions-will be used to conduct these panels. In addition to developing and testing the new engagement method, we will work with the members of our project's Advisory Board to generate a list of best practices for enhancing the level of patient and caregiver involvement in the guideline development process. We will solicit input on these best practice from Duchenne patients, caregivers, and clinicians by conducting a series of round-table discussions and making a presentation at an annual conference on Duchenne.

Results: The study protocol was reviewed by RAND's Human Subjects Protection Committee, which determined it to be exempt from review. Interviews with RAM experts have been completed. The projected study completion date is May 2020.

Conclusions: We expect that the new method will make it easier to engage large numbers of patients and caregivers in the process of guideline development in a rigorous and culturally appropriate manner that is consistent with the way clinicians participate in guideline development. Moreover, this project will develop best practices that could help involve patients and caregivers in the clinical guideline development process in other clinical areas, thereby facilitating the work of guideline developers.

Keywords: Delphi method; Duchenne muscular dystrophy; ExpertLens; guideline development; online stakeholder engagement panels; patient engagement.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: DK and SG are members of the ExpertLens team at RAND. SG’s spouse is a salaried employee of Eli Lilly and Company and owns stock. SG has accompanied his spouse on company-sponsored travel. All other coauthors report no conflicts of interest.

Figures

Figure 1
Figure 1
Round 1 mock-up screenshot.
Figure 2
Figure 2
Round 2 mock-up screenshot.

References

    1. Kelson M. Patient involvement in clinical guideline development. Where are we now? J Clin Gov. 2001;9:169–174.
    1. Grimshaw J, Eccles M, Russell I. Developing clinically valid practice guidelines. J Eval Clin Pract. 1995 Sep;1(1):37–48. - PubMed
    1. Cluzeau F, Wedzicha JA, Kelson M, Corn J, Kunz R, Walsh J, Schünemann HJ, ATS/ERS Ad Hoc Committee on Integrating and Coordinating Efforts in COPD Guideline Development Stakeholder involvement: how to do it right: article 9 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. Proc Am Thorac Soc. 2012 Dec;9(5):269–273. doi: 10.1513/pats.201208-062ST. - DOI - PubMed
    1. Schünemann HJ, Fretheim A, Oxman AD. Improving the use of research evidence in guideline development: 10. Integrating values and consumer involvement. Health Res Policy Syst. 2006 Dec 05;4:22. doi: 10.1186/1478-4505-4-22. https://health-policy-systems.biomedcentral.com/articles/10.1186/1478-45... - DOI - DOI - PMC - PubMed
    1. Chong C, Chen I, Naglie C, Krahn M. Do clinical practice guidelines incorporate evidence on patient preferences? Med Decis Making. 2007;27(4):E63–E64.

LinkOut - more resources